Search

Your search keyword '"Hu Xi-Chun"' showing total 266 results

Search Constraints

Start Over You searched for: Author "Hu Xi-Chun" Remove constraint Author: "Hu Xi-Chun"
266 results on '"Hu Xi-Chun"'

Search Results

1. The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

3. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitors

4. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

5. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study

6. Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective study

8. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

9. Age at initial diagnosis and prognosis of breast cancer: a nationwide multicenter retrospective study in China

12. Perceived Importance of Breast Cancer Risk Factors: A Survey on 386 Physicians in China

16. Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China

37. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

39. MONARCH_plus_supplement_27Jul20 – Supplemental material for MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study

42. Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy

43. Profile and outcome of receptor conversion in breast cancer metastases: a nation‐wide multicenter epidemiological study

44. Pyrotinib plus capecitabine for HER2-positive, trastuzumab-resistant metastatic breast cancer: A pooled analysis of three randomized controlled trials.

45. Pyrotinib combined with capecitabine as first-line therapy for HER2-positive metastatic breast cancer: A pooled analysis of three randomized controlled trials.

46. Efficacy and safety of liposomal mitoxantrone (Lipo-MIT) in advanced breast cancer (ABC): A randomized, open label, active-controlled, single-center, phase II clinical trial.

48. Gemcitabine or Abraxane Combined with cisPlatin (GAP) as First-Line Treatment in Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter, Randomized, Open-Label, Phase 3 Trial

49. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study

50. Breast Cancer: IL1R2 Blockade Suppresses Breast Tumorigenesis and Progression by Impairing USP15‐Dependent BMI1 Stability (Adv. Sci. 1/2020)

Catalog

Books, media, physical & digital resources